Bisphosphonate use in children with bone disease

Journal of the American Academy of Orthopaedic Surgeons

Volumn 14, Issue 12, 2006, Pages 638-644

  Hickey, Janelle ^a   Lemons, David ^a   Waber, Pamela ^b   Seikaly, Mouin G ^c,d  

^a CHILDREN S MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

CHILD; HUMAN; METABOLIC BONE DISEASE; REVIEW; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CHILD; DIPHOSPHONATES; HUMANS; TREATMENT OUTCOME;

EID: 33947662998     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/00124635-200611000-00006     Document Type: Review

References (33)

1. Forteo (teriparatide [rDNA origin] injection) product information [package insert]. Indianapolis, IN: Eli Lilly and Co, 2002.
2. Lin JT, Lane JM: Bisphosphonates. J Am Acad Orthop Surg 2003, 11:1-4.
3. Srivastava T, Alon US: The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003;162:735-751.
4. Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD: Diphosphonates in the treatment of myositis ossificans. Lancet 1969;2:845.
5. Dimeglio LA, Ford L, McClintock C, Peacock M: A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005;18:43-53.
6. Seikaly M, Kopanati S, Salhab N, et al: Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005;25: 786-791.
7. Lee YS, Low SL, Lim LA, Loke KY: Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160:641-644.
8. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
9. Plotkin H, Rauch F, Bishop NJ, et al: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-1850.
10. Zeitlin L, Rauch F , Plotkin H, Glorieux FH: Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003, 111(5 pt 1): 1030-1036.
11. Melchior R, Zabel B, Spranger J, Schumacher R: Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis. Eur J Pediatr 2005;164:22-27.
12. Brumsen C, Hamdy NA, Papapoulos SE: Long-term effects of bisphosphonates on the growing skeleton: Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:266-283.
13. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ: Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. J Pediatr 2002;141:644-651.
14. Bianchi ML, Cimaz R, Bardare M, et al: Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum 2000;43: 1960-1966.
15. Brantus JF, Meunier PJ: Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 1998;346:117-120.
16. Kos M, Luczak K, Godzinski J, Klempous J: Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg 2004;32:10-15.
17. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH: Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003; 88:4569-4575.
18. Robinson C, Baker N, Noble J, et al: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate. J Inherit Metab Dis 2002;25:681-693.
19. Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E: Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis: A pilot study using radiographic morphometry. Horm Res 2004;61:137-142.
20. Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD: Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 2005;86:284-288.
21. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim M: Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004;8:357-361.
22. Lepore L, Pennesi M, Barbi E, Pozzi R: Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991;(9 suppl):33-35.
23. Barr RD, Guo CY, Wiernikowski J, Webber C, Wright M, Atkinson S: Osteopenia in children with acute lymphoblastic leukemia: A pilot study of amelioration with pamidronate. Med Pediatr Oncol 2002;39:44-46.
24. Smith R: Fibrodysplasia (myositis) ossificans progressive: Clinical lessons from a rare disease. Clin Orthop Relat Res 1998;346:7-14.
25. Rogers JG, Dorst JP, Geho WB: Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr 1977;91:1011-1014.
26. Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C: Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002;115 suppl 3):929-937.
27. Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F: Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 2005;87:550-557.
28. Munns CF, Rauch F, Zeitlin F, Fassier F, Glorieux FH: Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19:1779-1786.
29. Wood GW: Fracture healing, in Canale ST (ed): Campbell's Operative Orthopaedics, ed 10. St. Louis, MO: Mosby, 2003, pp 2686-2690.
30. Adami S, Zamberlan N, Mian M, et al: Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 1994;25:75-82.
31. Novartis Pharmaceuticals: Dear Doctor Letter. http://www.fda.gov/ medwatch/SAFETY/2005/zometa_de ardentite_5-5-05.pdf. Accessed June 28, 2005.
32. Novartis Pharmaceuticals: Letter: Updated safety: Possible relationship of Aredia (pamidronate disodium) and/or Zometa (zoledronic acid) with osteonecrosis of the jaw. Ottawa, Canada: Health Canada, November 2004.
33. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.